康方生物(09926.HK)依达方肺癌新适应症上市申请获国家药监局批准

阿斯达克财经
Apr 28, 2025

康方生物(09926.HK) 公布,自主研发的全球首创双特异性抗体“依达方”(依沃西,PD-1/VEGF),单药用于PD-L1阳性(TPS=>1%)表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗新药上市申请,已获国家药监局批准上市,是该产品获批上市的第二个适应症。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10